血管紧张素 II 受体拮抗剂（AT 阻滞剂、ARB 类、沙坦类）：异同点
Angiotensin II receptor antagonists (AT-blockers, ARBs, sartans): similarities and differences.
作者信息
van Zwieten P A
出版信息
Neth Heart J. 2006 Nov;14(11):381-387.
Abstract
A survey is presented of the registered non-peptidergic angiotensin II receptor antagonists (AT blockers, ARBs, sartans) and their general properties and similarities. Accordingly, their receptor profile, pharmacokinetic and therapeutic applications are discussed. In addition, attention is paid to the individual characteristics of the AT blockers now available. A few components of this category offer additional potentially beneficial properties, owing to their pharmacological or metabolic characteristics. Such additional properties are critically discussed for eprosartan, losartan, telmisartan and valsartan.
摘要
本文介绍了已注册的非肽类血管紧张素II受体拮抗剂（AT阻断剂、ARB类、沙坦类）及其一般特性和相似之处。据此，讨论了它们的受体特征、药代动力学和治疗应用。此外，还关注了目前可用的AT阻断剂的个体特性。由于其药理或代谢特性，该类别的一些成分具有额外的潜在有益特性。对依普罗沙坦、氯沙坦、替米沙坦和缬沙坦的此类额外特性进行了批判性讨论。
相似文献
1
Angiotensin II receptor antagonists (AT-blockers, ARBs, sartans): similarities and differences.血管紧张素 II 受体拮抗剂（AT 阻滞剂、ARB 类、沙坦类）：异同点
Neth Heart J. 2006 Nov;14(11):381-387.
2
Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.血管紧张素II（AT1）受体阻滞剂在高血压治疗中的临床药代动力学
J Hum Hypertens. 2000 Apr;14 Suppl 1:S73-86. doi: 10.1038/sj.jhh.1000991.
3
Pharmacological properties of angiotensin II receptor antagonists.血管紧张素 II 受体拮抗剂的药理特性。
Can J Cardiol. 1999 Nov;15 Suppl F:26F-8F.
4
The place of ARBs in heart failure therapy: is aldosterone suppression the key?血管紧张素受体阻滞剂在心力衰竭治疗中的地位：醛固酮抑制是关键吗？
Ther Adv Cardiovasc Dis. 2019 Jan-Dec;13:1753944719868134. doi: 10.1177/1753944719868134.
5
Sympatho-inhibitory properties of various AT1 receptor antagonists.各种AT1受体拮抗剂的交感神经抑制特性。
J Hypertens Suppl. 2002 Jun;20(5):S3-11.
6
Pharmacology of AT1-receptor blockers.
Blood Press Suppl. 2001(3):5-10. doi: 10.1080/08037050152518302.
7
Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan.去大脑大鼠中交感神经传递易化作用及血管紧张素II诱导的升压效应的抑制：缬沙坦、坎地沙坦、依普罗沙坦和恩布沙坦之间的比较
J Hypertens. 2001 Dec;19(12):2241-50. doi: 10.1097/00004872-200112000-00018.
8
9
Sympatholytic properties of several AT1-receptor antagonists in the isolated rabbit thoracic aorta.几种AT1受体拮抗剂对离体兔胸主动脉的交感神经阻滞特性
J Hypertens. 2002 Sep;20(9):1821-8. doi: 10.1097/00004872-200209000-00028.
引用本文的文献
1
Angiotensin II receptor blockers induce autophagy in prostate cancer cells.血管紧张素II受体阻滞剂可诱导前列腺癌细胞发生自噬。
Oncol Lett. 2017 May;13(5):3579-3585. doi: 10.3892/ol.2017.5872. Epub 2017 Mar 17.
2
Drug Interactions in Parkinson's Disease: Safety of Pharmacotherapy for Arterial Hypertension.帕金森病中的药物相互作用：动脉高血压药物治疗的安全性
Drugs Real World Outcomes. 2015 Mar;2(1):1-12. doi: 10.1007/s40801-015-0008-7.
3
Pharmacogenomics Implications of Using Herbal Medicinal Plants on African Populations in Health Transition.使用草药对处于健康转型期的非洲人群的药物基因组学影响。
Pharmaceuticals (Basel). 2015 Sep 21;8(3):637-63. doi: 10.3390/ph8030637.
4
Angiotensin II receptor blockers: a new possible treatment for chronic migraine?血管紧张素II受体阻滞剂：慢性偏头痛的一种新的可能治疗方法？
Neurol Sci. 2015 Aug;36(8):1483-5. doi: 10.1007/s10072-015-2217-y. Epub 2015 Apr 28.
本文引用的文献
1
Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.血管紧张素受体阻滞剂：治疗靶点与心血管保护
Blood Press. 2005;14(4):196-209. doi: 10.1080/08037050500230227.
2
Comparative pharmacology of the angiotensin II receptor antagonists.
Expert Opin Investig Drugs. 1998 May;7(5):741-51. doi: 10.1517/13543784.7.5.741.
3
Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.阿利吉仑是一种新型口服有效的肾素抑制剂，在高血压患者中具有剂量依赖性的降压疗效和类似安慰剂的耐受性。
Circulation. 2005 Mar 1;111(8):1012-8. doi: 10.1161/01.CIR.0000156466.02908.ED. Epub 2005 Feb 21.
4
The role of olmesartan medoxomil in the management of hypertension.奥美沙坦酯在高血压管理中的作用。
Drugs. 2004;64(24):2731-9. doi: 10.2165/00003495-200464240-00002.
5
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.2型糖尿病合并肾病中血管紧张素受体阻滞剂与血管紧张素转换酶抑制剂的比较
N Engl J Med. 2004 Nov 4;351(19):1952-61. doi: 10.1056/NEJMoa042274. Epub 2004 Oct 31.
6
AT(1)-receptor blockade and sympathetic neurotransmission in cardiovascular disease.血管紧张素Ⅱ1型受体阻断与心血管疾病中的交感神经传递
Auton Autacoid Pharmacol. 2003 Oct-Dec;23(5-6):285-96. doi: 10.1111/j.1474-8673.2004.00301.x.
7
Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.血管紧张素1型受体阻滞剂可诱导过氧化物酶体增殖物激活受体γ活性。
Circulation. 2004 May 4;109(17):2054-7. doi: 10.1161/01.CIR.0000127955.36250.65. Epub 2004 Apr 26.
8
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.替米沙坦作为具有选择性过氧化物酶体增殖物激活受体γ调节活性的独特血管紧张素II受体拮抗剂的鉴定。
Hypertension. 2004 May;43(5):993-1002. doi: 10.1161/01.HYP.0000123072.34629.57. Epub 2004 Mar 8.
9
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.缬沙坦、卡托普利或两者联合用于治疗合并心力衰竭、左心室功能不全或两者皆有的心肌梗死。
N Engl J Med. 2003 Nov 13;349(20):1893-906. doi: 10.1056/NEJMoa032292. Epub 2003 Nov 10.
10
Candesartan and heart failure: the allure of CHARM.
Lancet. 2003 Sep 6;362(9386):754-5. doi: 10.1016/S0140-6736(03)14294-8.
Zotero 插件